イソクエン酸脱水素酵素（IDH）阻害剤の世界市場レポート2025年

イソクエン酸脱水素酵素（IDH）阻害剤市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年には年間平均成長率（CAGR）26.7%で63億4,000万米ドルに成長します。予測される成長は、有利な償還政策、血液がんの有病率の増加、腫瘍医の意識の高まり、精密医療の採用拡大、ヘルスケア・インフラと腫瘍センターの拡大などに起因すると考えられます。予測期間中に予想される主な動向としては、ゲノム・分子診断の進展、戦略的提携やライセンシング契約、ドラッグデリバリー・システムの革新、診断技術の主な発展、併用療法の開発などが挙げられます。

急性骨髄性白血病（AML）の罹患率の上昇が、今後数年間のイソクエン酸脱水素酵素（IDH）阻害剤市場の成長を牽引すると予想されます。AMLは急速に進行する血液および骨髄のがんで、白血球の異常増殖を特徴とし、正常な血球産生を阻害します。このAML症例の増加は、人口の高齢化に起因するところが大きいです。高齢者は、骨髄機能や免疫反応の加齢に関連した変化により、この侵攻性のがんを開発しやすくなるからです。IDH阻害剤は、変異したIDH酵素を標的として阻害することにより、正常な血球の発達を回復させ、白血病の進行を遅らせることによって、AMLの治療に重要な役割を果たしています。例えば、オーストラリアを拠点とする非営利団体Leukaemia Foundationの2023年2月の報告書によると、2022年から2035年の間に、7,000人以上の小児、6,000人以上の若年成人、10万8,000人以上の25歳から65歳の成人が血液がん、主に急性リンパ芽球性白血病（ALL）、AML、非ホジキンリンパ腫（NHL）と診断されると予想されています。その結果、AMLの頻度の増加がIDH阻害剤市場を大きく押し上げると予想されています。

イソクエン酸脱水素酵素（IDH）阻害剤市場の主要企業は、臨床適応の拡大、市場投入期間の短縮、IDH変異型がんの治療における競争力強化のため、薬事承認取得を優先しています。保健当局が承認する薬事承認は、医薬品の安全性と有効性を確認するものであり、商業的な上市に不可欠なものです。例えば、2024年8月、フランスの製薬会社セルヴィエ・ラボラトワールは、IDH1またはIDH2変異を有する星細胞腫や乏突起膠腫を含むグレード2のIDH変異グリオーマ患者を対象に承認された初の標的治療薬であるVORANIGO（ボラシデニブ）錠剤のFDA承認を取得しました。第3相INDIGO試験において、VORANIGOは無増悪生存期間中央値が27.7カ月であったのに対し、プラセボは11.1カ月でした。経口製剤は忍容性が高く、簡便な治療選択肢を提供し、既存の治療法が限られている患者にとって大きな進歩です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のイソクエン酸脱水素酵素（IDH）阻害剤：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場：成長率分析
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場の実績：規模と成長, 2019-2024
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• IDH1変異髄様悪性腫瘍
• IDH2変異髄様悪性腫瘍
• その他のタイプ
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場：分子タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ペプチド
• 小分子
• その他の分子タイプ
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 非経口
• 皮下
• 外用
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• FLT3阻害剤
• DH阻害剤
• ヘッジホッグ経路阻害剤
• その他の用途
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場、IDH1変異髄様悪性腫瘍のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性骨髄性白血病（AML）
• 神経膠腫または神経膠芽腫
• 胆管がん
• 軟骨肉腫
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場、IDH2変異髄様悪性腫瘍のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性骨髄性白血病（AML）
• 骨髄異形成症候群（MDS）
• 血管免疫芽球性T細胞リンパ腫（AITL）
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• IDH変異を伴う固形腫瘍
• IDH変異を伴う転移性がん
• 希少がんにおける実験的使用または適応外使用

第7章 地域別・国別分析

• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のイソクエン酸脱水素酵素（IDH）阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• イソクエン酸脱水素酵素（IDH）阻害剤市場：競合情勢
• イソクエン酸脱水素酵素（IDH）阻害剤市場：企業プロファイル
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Daiichi Sankyo Company Limited
• Les Laboratoires Servier
• Evotec SE
• HUTCHMED（China）Limited
• Rigel Pharmaceuticals Inc.
• CStone Pharmaceuticals
• Forma Therapeutics Holdings Inc.
• Philogen S.p.A.
• Kura Oncology, Inc.
• Philogen S.p.A.
• Agios Pharmaceuticals Inc.
• Adooq Bioscience LLC
• Taiho Pharmaceutical Co. Ltd.
• Celgene Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• イソクエン酸脱水素酵素（IDH）阻害剤市場2029：新たな機会を提供する国
• イソクエン酸脱水素酵素（IDH）阻害剤市場2029：新たな機会を提供するセグメント
• イソクエン酸脱水素酵素（IDH）阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Isocitrate dehydrogenase (IDH) Inhibitors are a category of targeted cancer treatments aimed at inhibiting the activity of mutated IDH1 and IDH2 enzymes. These enzymes play a role in cellular metabolism, and mutations in their genes can result in abnormal cell proliferation and cancer progression.

The primary types of isocitrate dehydrogenase (IDH) inhibitors include IDH1 mutant medullary malignant tumors, IDH2 mutant medullary malignant tumors, and others. An IDH1 mutant medullary malignant tumor is a cancer that begins in the central (medullary) part of a tissue or organ and involves a mutation in the IDH1 gene. These therapies encompass various molecular forms, such as monoclonal antibodies, peptides, small molecules, and others, and can be administered via oral, parenteral, subcutaneous, and topical routes. Applications include FLT3 inhibitors, DH inhibitors, hedgehog pathway inhibitors, and more.

The isocitrate dehydrogenase (IDH) inhibitors market research report is one of a series of new reports from The Business Research Company that provides isocitrate dehydrogenase (IDH) inhibitors market statistics, including isocitrate dehydrogenase (IDH) inhibitors industry global market size, regional shares, competitors with an isocitrate dehydrogenase (IDH) inhibitors market share, detailed isocitrate dehydrogenase (IDH) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the isocitrate dehydrogenase (IDH) inhibitors industry. This isocitrate dehydrogenase (IDH) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The isocitrate dehydrogenase (IDH) inhibitors market size has grown exponentially in recent years. It will grow from $1.94 billion in 2024 to $2.46 billion in 2025 at a compound annual growth rate (CAGR) of 27.0%. The growth during the historic period can be credited to the rising occurrence of hematologic cancers, advancements in genetic profiling within oncology, successful clinical outcomes of targeted therapies, the implementation of precision medicine initiatives, and increased healthcare expenditures in oncology.

The isocitrate dehydrogenase (IDH) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $6.34 billion in 2029 at a compound annual growth rate (CAGR) of 26.7%. The projected growth can be attributed to favorable reimbursement policies, an increasing prevalence of blood cancers, heightened awareness among oncologists, greater adoption of precision medicine, and the expansion of healthcare infrastructure and oncology centers. Key trends anticipated during the forecast period include progress in genomic and molecular diagnostics, strategic collaborations and licensing agreements, innovations in drug delivery systems, enhancements in diagnostic technologies, and the development of combination therapies.

The rising incidence of acute myeloid leukemia (AML) is expected to drive the growth of the isocitrate dehydrogenase (IDH) inhibitors market in the coming years. AML is a rapidly progressing cancer of the blood and bone marrow marked by the abnormal proliferation of white blood cells, which disrupts normal blood cell production. This increase in AML cases is largely attributed to the aging population, as older individuals are more susceptible to developing this aggressive cancer due to age-related changes in bone marrow function and immune response. IDH inhibitors play a crucial role in treating AML by targeting and blocking mutated IDH enzymes, thereby restoring normal blood cell development and slowing the progression of leukemia. For example, according to a February 2023 report by the Leukaemia Foundation, an Australia-based non-profit organization, between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25-65 are expected to be diagnosed with blood cancers, predominantly acute lymphoblastic leukemia (ALL), AML, and non-Hodgkin lymphoma (NHL). As a result, the growing frequency of AML is anticipated to significantly boost the IDH inhibitors market.

Major companies in the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing regulatory approvals to expand clinical indications, accelerate time-to-market, and strengthen their competitive positioning in the treatment of IDH-mutant cancers. Regulatory approvals, granted by health authorities, confirm a drug's safety and efficacy and are essential for commercial launch. For example, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets-the first targeted therapy approved for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. In the Phase 3 INDIGO trial, VORANIGO demonstrated a median progression-free survival of 27.7 months compared to 11.1 months with placebo. The oral formulation offers a well-tolerated and convenient treatment option, representing a significant advancement for patients with limited existing therapies.

In October 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Forma Therapeutics for $1.1 billion. The acquisition aims to strengthen Novo Nordisk's scientific capabilities and pipeline in hemoglobinopathies by expanding its portfolio to include treatments for sickle cell disease and other rare blood disorders. Forma Therapeutics, a US-based biopharmaceutical company, is known for developing innovative therapies for various cancers, including those targeting mutated isocitrate dehydrogenase (IDH).

Major players in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC.

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in isocitrate dehydrogenase (IDH) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The isocitrate dehydrogenase (IDH) inhibitors market consists of sales of selective IDH1 inhibitors, selective IDH2 inhibitors, dual IDH1/IDH2 inhibitors, combination therapies, and delivery forms. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods, such as formulation development, packaging, and regulatory support.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on isocitrate dehydrogenase (idh) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for isocitrate dehydrogenase (idh) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The isocitrate dehydrogenase (idh) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: IDH1 Mutant Medullary Malignant Tumor; IDH2 Mutant Medullary Malignant Tumor; Other Types
• 2) By Molecule Type: Monoclonal Antibodies; Peptides; Small Molecules; Other Molecule Types
• 3) By Route Of Administration: Oral; Parenteral; Subcutaneous; Topical
• 4) By Application: FLT3 Inhibitor; DH Inhibitor; Hedgehog Pathway Inhibitor; Other Applications
• Subsegments:
• 1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML); Glioma Or Glioblastoma; Cholangiocarcinoma; Chondrosarcoma
• 2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); Angioimmunoblastic T-Cell Lymphoma (AITL)
• 3) By Other Types: Solid Tumors With IDH Mutations; Metastatic Cancers With IDH Alterations; Experimental Or Off-Label Uses In Rare Cancers
• Companies Mentioned: Roche Holding AG; Merck & Co., Inc.; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Isocitrate Dehydrogenase (IDH) Inhibitors Market Characteristics

3. Isocitrate Dehydrogenase (IDH) Inhibitors Market Trends And Strategies

4. Isocitrate Dehydrogenase (IDH) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth Rate Analysis
• 5.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Isocitrate Dehydrogenase (IDH) Inhibitors Total Addressable Market (TAM)

6. Isocitrate Dehydrogenase (IDH) Inhibitors Market Segmentation

• 6.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IDH1 Mutant Medullary Malignant Tumor
• IDH2 Mutant Medullary Malignant Tumor
• Other Types
• 6.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Peptides
• Small Molecules
• Other Molecule Types
• 6.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Subcutaneous
• Topical
• 6.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• FLT3 Inhibitor
• DH Inhibitor
• Hedgehog Pathway Inhibitor
• Other Applications
• 6.5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH1 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Myeloid Leukemia (AML)
• Glioma Or Glioblastoma
• Cholangiocarcinoma
• Chondrosarcoma
• 6.6. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH2 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Myeloid Leukemia (AML)
• Myelodysplastic Syndromes (MDS)
• Angioimmunoblastic T-cell Lymphoma (AITL)
• 6.7. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solid Tumors with IDH Mutations
• Metastatic Cancers With IDH Alterations
• Experimental Or Off-label Uses In Rare Cancers

7. Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional And Country Analysis

• 7.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 8.1. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 9.1. China Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 9.2. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 10.1. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 11.1. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 11.2. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 12.1. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 13.1. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 14.1. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 14.2. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 15.1. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 15.2. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 16.1. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 17.1. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 18.1. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 19.1. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 20.1. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 21.1. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 21.2. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 22.1. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 23.1. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 23.2. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 24.1. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 24.2. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 25.1. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 25.2. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 26.1. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 26.2. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 27.1. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 28.1. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 28.2. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market

• 29.1. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
• 29.2. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Landscape
• 30.2. Isocitrate Dehydrogenase (IDH) Inhibitors Market Company Profiles
  • 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Isocitrate Dehydrogenase (IDH) Inhibitors Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Daiichi Sankyo Company Limited
• 31.3. Les Laboratoires Servier
• 31.4. Evotec SE
• 31.5. HUTCHMED (China) Limited
• 31.6. Rigel Pharmaceuticals Inc.
• 31.7. CStone Pharmaceuticals
• 31.8. Forma Therapeutics Holdings Inc.
• 31.9. Philogen S.p.A.
• 31.10. Kura Oncology, Inc.
• 31.11. Philogen S.p.A.
• 31.12. Agios Pharmaceuticals Inc.
• 31.13. Adooq Bioscience LLC
• 31.14. Taiho Pharmaceutical Co. Ltd.
• 31.15. Celgene Corporation

32. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Isocitrate Dehydrogenase (IDH) Inhibitors Market

34. Recent Developments In The Isocitrate Dehydrogenase (IDH) Inhibitors Market

35. Isocitrate Dehydrogenase (IDH) Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer